---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-084852"
form_type: "8-K"
ticker: null
cik: "0001580063"
company_name: "BIORA THERAPEUTICS, INC."
filed_at: "2024-04-02T23:59:59+00:00"
generated_at: "2026-06-04T03:33:36.495120+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biora prices $6M registered direct offering of 5.45M shares at $1.10; warrants also issued

## Summary
- Gross proceeds of ~$6M from sale of 5,454,548 shares at $1.10 per share.
- Issued warrants to purchase 5,454,548 shares at $1.10; exercisable after stockholder approval.
- Amended existing warrants to lower exercise price to $1.10 and extend term to 5 years post-approval.
- Entered voting agreements with Athyrium and officers/directors to support stockholder approval.
- Expected closing on April 3, 2024; H.C. Wainwright acted as placement agent.

## SEC filing metadata
- accession: 0001193125-24-084852
- form_type: 8-K
- cik: 0001580063
- company_name: BIORA THERAPEUTICS, INC.
- filed_at: 2024-04-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1580063/000119312524084852/0001193125-24-084852-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1580063/000119312524084852/d816753d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-084852
- JSON: https://secwatch.observer/filing/0001193125-24-084852.json
- Plain text: https://secwatch.observer/filing/0001193125-24-084852.txt

## Key facts
- Material Agreements
  BIORA THERAPEUTICS, INC. entered into Purchase Agreement with certain institutional and accredited investors valued at approximately $6 million (effective 2024-03-31).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional and accredited investors
  - Value: approximately $6 million
  - Effective: 2024-03-31
  source text: On March 31, 2024, Biora Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement with certain institutional and accredited investors (the “Purchase Agreement”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1580063/000119312524084852/0001193125-24-084852-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.